Adenosine A2a Receptor Antagonist for NSCLC Immune Evasion

Solution Overview

Problem

Current treatments for non-small cell lung cancer (NSCLC) have limited efficacy and are associated with significant toxicity, and there is a need for novel therapies that can effectively target the adenosine-mediated immunosuppressive mechanisms used by tumors to evade immune surveillance.

Innovation Solution

The development of 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts, and co-crystals, which act as potent adenosine A2a receptor antagonists, combined with immunotherapeutic agents like PD-1 and PD-L1 inhibitors to boost the immune system and inhibit tumor evasion mechanisms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for non-small cell lung cancer are used, then cancer therapy is provided, but efficacy is limited and toxicity is significant

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by developing a novel chemical compound (5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine) with specific molecular structure parameters that selectively target adenosine A2a receptors. This compound exhibits enhanced potency and selectivity compared to existing treatments, achieving better anti-tumor efficacy while reducing off-target toxicity through optimized chemical parameters

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention uses the adenosine A2a receptor antagonist as an intermediary substance that blocks the immunosuppressive adenosinergic pathway in the tumor microenvironment. This intermediary compound prevents adenosine from suppressing immune cells, thereby restoring immune-mediated anti-tumor activity without directly cytotoxic to cancer cells, reducing treatment toxicity

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If adenosine-mediated immunosuppressive mechanisms are targeted, then immune response against tumor is enhanced, but treatment complexity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the specific adenosine A2a receptor pathway as the target for intervention. By focusing on this single dominant immunosuppressive mechanism rather than attempting to modulate the entire adenosinergic system or multiple immune pathways simultaneously, the treatment simplifies the therapeutic approach while effectively enhancing immune response against the tumor

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention creates a simplified model of immune enhancement by using a small molecule antagonist that replicates the effect of blocking adenosine signaling. This single compound copies and amplifies the natural immune response without requiring complex combination therapies or multiple intervention points, reducing treatment complexity

Inventive Principle:
Principle #26Copying

Data Source

PatentEP3334431B95-bromo-2,6-di-(1h-pyrazol-l-YL)pyrimidin-4-amine for use in the treatment of cancer
Publication Date: 2020.03.04
  • EP3334431B9 patent drawingFigure 1a~1b
  • EP3334431B9 patent drawingFigure 1c~2
  • EP3334431B9 patent drawingFigure 3~4

AI summary

The present invention relates to 5-bromo-2,6-di-(1 H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.